This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vogel, C. L. Articles by Hohneker, J. A. Search for Related Content PubMed PubMed Citation Articles by Vogel, C. L. Articles by Hohneker, J. A.

Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy

^a Cancer Research Network, Plantation, Florida, USA; ^b Gilroy Private Practice, Gilroy, California, USA; ^c Cancer Specialist of South Texas, Corpus Christi, Texas, USA; ^d Central Georgia Hematology Oncology Associates, Macon, Georgia, USA; ^e Peachtree Hematology/Oncology Associates, Atlanta, Georgia, USA; ^f Queens Medical Associates, Fresh Meadows, New York, USA; ^g Hematology Oncology Associates of Albuquerque, Albuquerque, New Mexico, USA; ^h Northwestern Carolina Hematology/Oncology, Hickory, North Carolina, USA; ⁱ Novartis Oncology, Florham Park, New Jersey, USA

Correspondence: Charles L. Vogel, M.D., Cancer Research Network, 350 NW 84th Avenue, Suite 305, Plantation, Florida 33324, USA. Telephone: 954-473-6776; Fax: 954-473-4552; e-mail: drcvogel{at}aol.com

An open-label study conducted in community centers assessed the safety of zoledronic acid 4 mg intravenously over 15 minutes every 3–4 weeks as treatment of bone metastases in patients with multiple myeloma, breast cancer, or prostate cancer with and without previous bisphosphonate exposure. Adverse events (AEs), pain, and quality-of-life (QOL) scores were recorded, and serum creatinine (SCr) levels were measured before each infusion. Of 638 patients, 415 patients (65%) had received prior bisphosphonate therapy. Fatigue, nausea, and arthralgia were the most frequent AEs. Nausea was more common in bisphosphonate-naïve patients. SCr levels increased notably in 6.6% of patients: 7.7% of patients who received prior bisphosphonate therapy and 4.5% of bisphosphonate-naïve patients. Treatment was delayed because of SCr-level increases in 1.4% of patients with prior bisphosphonate exposure and 0.4% of bisphosphonate-naïve patients. SCr-level increases and treatment delays did not correlate with duration of prior bisphosphonate therapy. There was a trend towards more treatment discontinuations in patients with prior bisphosphonate exposure compared with bisphosphonate-naïve patients. Pain scores decreased from baseline; total QOL scores remained constant. The results of this study suggest that, with proper SCr-level monitoring, cancer patients with bone metastases who have previously received intravenous bisphosphonate treatment can be safely converted to zoledronic acid therapy.

Key Words. Zoledronic acid • Pamidronate • Bisphosphonate • Bone metastases

This article has been cited by other articles:

				M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]

				C. Gridelli The Use of Bisphosphonates in Elderly Cancer Patients Oncologist, January 1, 2007; 12(1): 62 - 71. [Abstract] [Full Text] [PDF]

				R. Bell Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Oncologist, October 1, 2005; 10(suppl_1): 8 - 13. [Abstract] [Full Text] [PDF]